A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206

Several studies have reported improvement in lipids after antiretroviral therapy switches to tenofovir disoproxil fumarate (TDF)-containing regimens. We assessed lipid-lowering effects of TDF by adding it to a stable antiretroviral therapy regimen in this double-blind, placebo-controlled crossover s...

Full description

Saved in:

Bibliographic Details
Published in:	AIDS (London) Vol. 24; no. 11; pp. 1781 - 1784
Main Authors:	TUNGSIRIPAT, Marisa, KITCH, Douglas, GLESBUY, Marshall J, GUPTA, Samir K, MELLORS, John W, MORAN, Laura, JONES, Lynne, ALSTON-SMITH, Beverly, ROONEY, James F, ABERG, Judith A
Format:	Journal Article
Language:	English
Published:	Hagerstown, MD Lippincott Williams & Wilkins 17-07-2010
Subjects:	Adenine - analogs & derivatives Adenine - therapeutic use Adult Aged Anti-HIV Agents - therapeutic use Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral Therapy, Highly Active - adverse effects Antiretroviral Therapy, Highly Active - methods Antiviral agents Biological and medical sciences Cholesterol - blood Dyslipidemias - blood Dyslipidemias - drug therapy Dyslipidemias - etiology Epidemiologic Methods Female HIV Infections - blood HIV Infections - complications HIV Infections - drug therapy HIV-1 Human immunodeficiency virus Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious diseases Male Medical sciences Middle Aged Organophosphonates - therapeutic use Pharmacology. Drug treatments Pilot Projects Tenofovir Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Young Adult Immunopathology Purine nucleotide Antiretroviral agent Acyclic nucleotide RNA-directed DNA polymerase Enzyme Transferases Enzyme inhibitor Metabolic diseases Lipids AIDS Organic phosphonate Nucleotide analog Immune deficiency Infection Tenofovir Nucleotidyltransferases Chemotherapy Treatment Reverse transcriptase inhibitor Viral disease Nucleoside analog Antiviral Dyslipemia
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Several studies have reported improvement in lipids after antiretroviral therapy switches to tenofovir disoproxil fumarate (TDF)-containing regimens. We assessed lipid-lowering effects of TDF by adding it to a stable antiretroviral therapy regimen in this double-blind, placebo-controlled crossover study. We demonstrated that nonhigh-density lipoprotein cholesterol, low-density lipoprotein cholestrol, and total cholestrol improved significantly over TDF vs. placebo treatment in HIV-infected individuals with dyslipidemia. Adding TDF to stable, virologically suppressive antiretroviral therapy regimens improved lipid parameters, supporting a lipid-lowering effect of TDF.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
ISSN:	0269-9370 1473-5571
DOI:	10.1097/qad.0b013e32833ad8b4